An analysis of the current situation of China's small and medium-sized enterprises to accelerate the formation of new forces of health

General Secretary Xi Jinping and Premier Li Keqiang have repeatedly stressed that "small, small, living", stable employment, the economy is alive.
, SMEs contribute more than 50% of tax revenue, more than 60% of GDP, more than 70% of technological innovation, more than 80% of urban labor and employment, and more than 90% of the number of enterprises.
the 19th National Congress of the People's Congress proposed to speed up the construction of an innovative country, with special emphasis on strengthening support for innovation in small and medium-sized enterprises and promoting the transformation of scientific and technological achievements.
development vitality of small and medium-sized innovative enterprises, which is related to the realization of the goal of building an innovative country.
people's health is the basis of social civilization progress and economic and social development, but also the symbol of national prosperity and national prosperity and strength.
outbreak is not only a test of the global public health system and capabilities, but also brings new enlightenment and tasks to the field of China's great health.
same time, in the course of serving the development of biopharmaceutical industry in parks and local governments, we see that the development mode and industrial ecology of the whole industry are changing, and innovative small and medium-sized enterprises are increasingly becoming important variable factors affecting the industrial pattern.
, the development of small and medium-sized enterprises are facing three major challenges 1. Small and medium-sized enterprises information matching ability is weak, affecting the efficiency of enterprises reaching resources.
Small and medium-sized enterprises (SMEs) are relatively small in size and their teams are dominated by research and development personnel, so their ability to find and collect information is relatively inadequate and lacks the ability to accurately match service providers and accurately seek policy support.
2. Small and medium-sized enterprises (SMEs) have weak capacity for resource integration, and there are many challenges to reducing efficiency.
In the field of biopharmaceuticals supply chain goods and services are extremely complex, enterprises in the actual research and development production, it takes a lot of manpower, material resources and time to find the right resources, and often there are found resources and the actual can not match the situation, resulting in their enterprises cost-effectiveness there are many challenges.
3. The adaptive capacity of small and medium-sized enterprises is weak, and the survival and development of the new environment face many external challenges.
The digital economy and bioeconomy are profoundly changing the mode of production and lifestyle of the society and economy, and enterprises need to constantly adapt to the rapidly changing consumption needs, adapt to the rapid iteration and innovation of new technologies and new business models, in order to cope with the existential crisis and promote their own business upgrading.
combined with the new global economic and political environment, industrial chain safety, industrial precision management and innovation ecology of small and medium-sized enterprises have increasingly become key factors in promoting the high quality and efficient development of industry.
in the special historical pass, how to achieve the combination of small and medium-sized enterprises "protection" and "promote", so that small and medium-sized enterprises become a new force in the industry, is the government and entrepreneurs can not avoid the proposition of the times.
Second, innovation is easier, how can the new practice of SME service really penetrate and cut into the value chain of SME business, form adaptive and self-matching development momentum, enhance enterprise operation ability and enhance enterprise development potential energy? Under the background of big data era, the mobility and efficiency of data provide a new solution path for small and medium-sized enterprises with scientific and technological innovation to improve the matching efficiency of innovation supply and demand and reduce operating costs, and take the lead in the vertical scenario of biomedicine.
Biopharmaceutical industry has the characteristics of highly clustered small and medium-sized enterprises, the industry is being driven by a small number of large enterprises to a large number of small and medium-sized innovative enterprises, the number of enterprises listed in China's science and technology board, the number of enterprises in the field of biopharmaceuticals ranked second.
At the same time, the biopharmaceutical industry has the characteristics of "three highs and one long" (high technology, high investment, high risk, long cycle), especially for small and medium-sized innovative enterprises with weak resource integration ability and weak financial strength.
Small and medium-sized start-ups need to build a complete supply chain for 2-3 years or more, import a reagent takes 2-3 months or even half a year, will also encounter due to the impact of trade war on certain products can not be imported, some entrepreneurs labored, time-consuming to find suppliers, only to find that the cooperative agencies in a park, even next door.
After analysis of several reasons, although the industry market growth is fast, but China's pharmaceutical research and development enterprises as a whole small size, weak bargaining power of enterprises, coupled with the industry innovation services in China is in its infancy, with large-scale, specialized service capabilities such as INSTITUTIONs such as CRO, raw materials and core components suppliers in the development stage, weak service capacity and distribution is not centralized, so that small enterprises in innovative service resources link, service bargaining and other aspects of the enterprise is difficult to obtain high-quality resources.
, work together to help accelerate the formation of new forces of health integration and development is the key.
The former president of the PLA General Hospital and executive vice president of the China Health Management Association, Ren Guoxuan, believes that in view of the current increasingly complex and changing international situation, it is necessary to solve the problem of relatively few high-tech, low quality of development, improve the production chain of key technologies, supply chain, change the difficulties, difficulties and risks that are subject to people.
enterprises to combine the actual, key technology to be in their own hands, product key production links can not be completely dependent on foreign countries.
medical science and technology is a complex system engineering, cultivating new forces needs fusion development.
The number of medical enterprises in China is huge, each has its own advantages, each has its place, it is impossible to stand alone, mutual benefit between enterprises can win-win situation, cooperation can jointly build a good China's industrial chain and supply chain.
Cultivating new forces needs to change the pattern from many aspects, such as the need for independent union between enterprises, breaking down barriers, making up for each other' strengths, rational division of labor, coordinated development, mergers of old and new enterprises, with the main purpose of adjusting product layout, sharing of enterprise resources, eliminating unnecessary opposition and bad market competition, working hard to create a guardian brand;
vigorously promote institutional innovation.
Zhang Shiping, deputy director of the Social and Legal Affairs Committee of the 12th CPPCC National Committee, former vice chairman of the All-China Federation of Trade Unions, secretary of the Secretariat and director of the Expert Steering Committee of the China Health Management Association, believes that medical and health enterprises are the intermediate force for the development of large-scale health industry to achieve full life-cycle health management, and need to be based on the new stage of development, review the situation, re-position themselves and change the development model.
explore new paths of high-quality, efficient and sustainable development, highlight features to build brands, promote the transformation and use of modern medical achievements, and form their own core competitiveness.
must not stand alone, we must share resources, complementary advantages.
From the national level, we need to vigorously promote institutional innovation, break through the limitations of the health system from a medical perspective, and actively build a new health service system with higher efficiency, wider coverage, greater space and more in line with the needs of people's livelihood and social development, complementing the existing medical system.
make a new contribution to showcasing new scenes.
Jin Xiaotao, a former member and deputy director of the Party Group of the National Health Planning Commission and president of the China Society of Health Information and Health Care Big Data, said the new force has potential and strength to contribute more to China's big health industry.
health industry as a sunrise industry, has a huge space for development, is a new strategic industry, the new force will bring great upgrading to the development of China's health industry.
, the application of science and technology, cutting-edge technology and emerging information technology in the fight against the epidemic has achieved good results.
includes a series of new technologies, new business models and new models in Internet medical care, online registration, medical settlement, distribution logistics, and remote services.
Since the reform and opening-up, medical and health undertakings have made great progress, but there are also problems that can only be solved in the reform on the demand side and the supply side, and the display of new scenes after the new forces enter the market needs to continue to innovate jointly, thus making new contributions to the digital health industry economy.
China's biopharmaceutical innovation is changing from a few large enterprises to a collaborative development model, to more small and medium-sized enterprises to participate in the open platform and open ecological construction.
expect small and medium-sized enterprises in new technologies, new models, accelerate the formation of China's new health forces, and truly build the first camp of China's medical and health industry development, China's health industry transformation and upgrading, to build industrial competitiveness of the main force.
at the same time in the industry support, this force can stand up to the tide, go deep, highlighting the revitalization and rise of China's pharmaceutical industry.
。